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Observational epidemiology is continually held to the
standard of randomized trials. A typical epidemiology
article references previous trials in the introduction (or
reasons why trials are not feasible) and, when possible,
compares the results to previous trials in the discussion.
When the results from an observational study and trial
disagree, we nearly always begin by questioning the for-
mer. Curiously, the methods section of an observational
study—an undeniably crucial part of an article—rarely
references trial methods or designs. Explicit target trial
emulation aims to remedy this.
Target trial emulation is the application of design prin-
ciples from randomized trials to the analysis of observa-
tional data, thereby explicitly tying the analysis to the trial
it is emulating. The purpose is to improve the quality of
observational epidemiology through the application of trial
design principles, even when, or perhaps especially when, a
comparator trial is not yet available or feasible [1]. In this
issue of the European Journal of Epidemiology, Garcı´a-
Albe´niz and colleagues [2] use observational data to
compare effect estimates of colon cancer screening on
cancer incidence over eight years of follow up using trial
emulation alongside more commonly used analytic
approaches. By precisely specifying their target trial’s
eligibility criteria, treatment strategies, treatment assign-
ment, follow-up period, outcome, causal contrast, and
statistical analysis, they illustrate the value of emulating a
well-specified target trial and show how common analytic
approaches would be inappropriate.
Indeed, as others have also highlighted (e.g., [1–5]),
emulating a target trial (and the formal causal frameworks
it is compatible with) can help researchers identify and
avoid unnecessary biases and provide a clear means for
articulating the tradeoffs we may need to make in our
observational studies. Unfortunately, we cannot always
emulate the core elements of an ideal trial: it is usually not
possible to emulate blinding, for example, or we may be
forced to choose different eligibility criteria due to data
availability considerations. Likewise, perhaps we cannot
measure enough baseline confounders to emulate random
assignment, and therefore consider alternative analytic
strategies that may be valid but change the intervention or
eligibility criteria in essential ways [6, 7]. Based on
available measures or available knowledge, our interven-
tion of interest may not be sufficiently well-defined, and
describing the ill-defined target trial forces us to see that
tradeoff [4, 8]. In some cases, even if we cannot emulate
the ideal trial, we may still pursue the study while con-
scious of the compromises made. In other cases, we may
realize the trial we are able to emulate is making tradeoffs
that are too big and we may therefore choose to refine our
questions or seek other data. Both of these outcomes are
productive to the end-goal of improving epidemiologic
research.
Here, we reflect on the contributions made by Garcı´a-
Albe´niz et al. as well as other recent publications that
embrace the trial analogy to discuss the broader potential
impact of this idea. Given that others have previously
discussed how trial emulation can improve epidemiologic
research [1, 3, 4], we will focus on the impact trial emu-
lation could have on the teaching of epidemiology as well
as potential further methodologic advances it may inspire.
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Target trials in the classroom
Most important advances in epidemiologic methods in
recent decades have been coupled with increased com-
plexity both statistically and in the assumptions required
for unbiased estimation. As much as g-methods, quasi-
experimental methods, and other causal inference tools
have improved the quality of observational research,
understanding these methods well enough to apply them
properly requires a substantial time investment. Trial
emulation is different in this respect because the knowl-
edge required to understand and apply it is already part of
the traditional epidemiology curriculum. Garcı´a-Albe´niz
et al. are not applying new methodologic principles per se:
they are carefully applying design principles from trials to
observational data where they have sometimes not been
applied judiciously. In order to teach trial emulation to
epidemiologists, introductory epidemiology courses
require little augmentation. No new vocabulary or mathe-
matical notation is needed beyond that already included in
the teaching of trials. In fact, the inclusion of trial emula-
tion creates a logical transition from the teaching of trials
to observational research [9].
One nice consequence of teaching causal inference
principles via trial emulation is that it clarifies immediately
why some analytic practices are problematic. Consider how
Garcı´a-Albe´niz et al. describe the two common but biased
approaches they conduct alongside their preferred analysis.
Without the trial emulation framework, the rationale
behind these biased approaches can appear to be logical.
However, if one were taught from the beginning to think in
terms of trial emulation, their flaws could quickly be
identified. For example, when examining the cumulative
incidence curves of each analysis, it is clear that only the
trial emulation analyses would be able to reproduce the
crossing curves expected in a screening trial [10, 11]. In
addition to avoiding biases, the framework also reveals
opportunities for using available data more efficiently,
although this involves more methodologic complexity that
may be best taught in an intermediate or advanced course.
It seems clear that trial emulation should be a core
component to how causal inference gets taught in epi-
demiology curriculum. The heuristic questions that remain
are when and to whom it should be taught, how much
emphasis should it be given, and whether potential negative
consequences exist if trial emulation becomes common-
place. Educators need to weigh whether the trial emulation
merits displacing other core material in epidemiology
courses; alternatively, it is possible that its inclusion
streamlines or better conveys the fundamentals of obser-
vational epidemiology that are already taught in
introductory classes and better connects those fundamen-
tals to the statistical analyses taught in advanced classes.
Educators who teach epidemiology to non-epidemiologists
(e.g., policy-makers; medical researchers from other dis-
ciplines) may also see their students’ comprehension
improving, as trial emulation seems more readily accessi-
ble than teaching causal diagrams or counterfactual nota-
tion while still being able to convey the same foundational
principles.
Beyond the classroom
Beyond improving teaching and specific research applica-
tions, embracing a trial emulation framework can provide
opportunities for epidemiologists to be more creative with
the scientific process. (It will be important, of course, to
formalize and assess any such broadened methods.) Here
we briefly describe two such examples.
First, consider the setting from Garcı´a-Albe´niz et al. in
which they emulate a target trial of screening colonoscopy
knowing that actual randomized trials are on-going but will
not be published for years to come. If their study and
studies emulating related target trials in other data all
demonstrate similar long-term benefits of colonoscopies,
would we necessarily need to wait for a decade of follow-
up time to accrue in the actual trials to gain confidence in
the effects of colonoscopy? Even after a shorter follow-up
time from the actual trials, it is possible to see whether the
short-term causal effects estimated in observational studies
closely mirror what is seen at that point in the trials. If they
indeed map closely onto one another, it may serve as an
indication that our observational study is on the right track
and make us more confident that we can make colonoscopy
recommendations much sooner than waiting for the full
results of the trial. If they do not map closely onto one
another, it may motivated us to re-examine the means by
which we emulated random assignment (e.g., what
unmeasured confounding could remain?). However, even if
random assignment is successfully emulated, it is important
to note that trial emulation will not guarantee compara-
bility with real trials. Differences between populations
being studied or other reasons the target trial protocol is not
exactly aligned with the real trial may also cause estimates
to differ [12]. By understanding when and why results
agree, however, we can combine the powers of observa-
tional studies and actual on-going trials to support more
timely conclusions, and continue to refine those conclu-
sions as the trials continue.
Second, consider the rather common setting of studying
some treatment’s effect on a rare outcome, such as the
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effect of statin medications on cardiovascular disease and
death. To conduct a trial in a population of all indicated
patients with a suitable sample size may not be feasible;
instead, trialists may conduct a trial in a high-risk popu-
lation (so that the outcome is not expected to be so rare) or
they may study a surrogate outcome such as cholesterol
levels. Neither is necessarily answering the questions most
pressing to policy-makers, clinicians, or patients. With an
observational study we could emulate the trial as conducted
to see whether our estimates coincide with the trial. Armed
with this ‘‘validation’’ of our observational study results,
we can modify the target trial in our observational analysis
to estimate other quantities such as effects in a more
heterogeneous population or effects on endpoints of inter-
est rather than surrogate endpoints. That is, we can com-
bine results from actual randomized trials that did not
target exactly the ideal question with the powers of
observational studies to support more robust conclusions
beyond those produced by a trial or an observational study
alone.
Conclusions
The degree to which explicit target trial emulation in
observational studies aligns with results from well-con-
ducted trials remains to be seen. The results thus far are
encouraging (e.g., [2, 5, 13]) but studies that emulate a trial
before the trial results are known, such as Garcı´a-Albe´niz
et al. will be important. We believe, however, that the
principles behind trial emulation ought to be adopted
regardless because they encourage known good practices.
The immediate benefits of trial emulation have been
outlined here and by others [1, 3, 4], but the impact of trial
emulation goes beyond improving individual studies and
into the classroom and how we can approach the scientific
process as a whole. We thank Garcı´a-Albe´niz et al. for
providing an excellent example to use in teaching trial
emulation. When the colonoscopy randomized trials are
published, we are sure their paper will be even more useful
in the classroom, regardless of whether the results align. It
remains to be seen, however, whether it will then serve to
teach our future students about the value of trial emulation,
the need for humility when estimating causal effects, the
iterative nature of scientific findings, or most likely a
combination of all of the above.
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